untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:05Z</responseDate>
<request identifier=oai:HAL:hal-00875284v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875284v1</identifier>
<datestamp>2018-01-11</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UPEC-UPEM</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UNIV-PSUD</setSpec>
<setSpec>collection:UCA-TEST</setSpec>
<setSpec>collection:UNIV-COTEDAZUR</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.</title>
<creator>Bommenel, Tchadie</creator>
<creator>Launay, Odile</creator>
<creator>Meynard, Jean-Luc</creator>
<creator>Gilquin, Jacques</creator>
<creator>Katlama, Christine</creator>
<creator>Lascaux, Anne-Sophie</creator>
<creator>Mahamat, Aba</creator>
<creator>Martinez, Valérie</creator>
<creator>Pradier, C.</creator>
<creator>Rouveix, Elisabeth</creator>
<creator>Simon, A.</creator>
<creator>Costagliola, Dominique</creator>
<creator>Abgrall, Sophie</creator>
<creator>Michelet, Christian</creator>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>CIC - Biotherapie - AP-HP (cochin - Pasteur) ; Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service des maladies infectieuses et tropicales [CHU Saint-Antoine] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP]</contributor>
<contributor>Hôtel-Dieu ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôtel-Dieu</contributor>
<contributor>Service d'immunologie clinique [Créteil] ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)</contributor>
<contributor>Service des maladies infectieuses, Hopital Andree Rosemond ; Hopital Andree Rosemon</contributor>
<contributor>Cytokines, chimiokines et immunopathologie ; Université Paris-Sud - Paris 11 (UP11) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Public Health Department, Hôpital de l'Archet ; CHU Nice</contributor>
<contributor>Service de Médecine Interne ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Ambroise Paré</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0305-7453</source>
<source>EISSN: 1460-2091</source>
<source>Journal of Antimicrobial Chemotherapy</source>
<publisher>Oxford University Press (OUP)</publisher>
<identifier>hal-00875284</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875284</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875284</source>
<source>Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2011, 66 (8), pp.1869-77. 〈10.1093/jac/dkr208〉</source>
<identifier>DOI : 10.1093/jac/dkr208</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkr208</relation>
<identifier>PUBMED : 21636583</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/21636583</relation>
<language>en</language>
<subject lang=en>HIV/AIDS</subject>
<subject lang=en>switch</subject>
<subject lang=en>virological effectiveness</subject>
<subject lang=en>boosted protease inhibitor</subject>
<subject lang=en>cohort study</subject>
<subject>[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVES: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir. METHODS: From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir. Each of these patients was matched with three patients who continued to take their first-line cART regimen, on the basis of gender, age, CD4 cell count, VL, date of cART initiation and the duration of VL undetectability. Time to virological failure (VF) was analysed with Kaplan-Meier curves and Cox models. RESULTS: The 12 month probabilities of VF were 3.7% and 5.7% in non-switch and switch patients, respectively, and 3.9%, 7.2% and 9.0% in patients switching to efavirenz-, nevirapine- and abacavir-containing cART, respectively. After adjustment, only patients switching to abacavir-containing cART had a higher risk of VF than non-switch patients (adjusted hazard ratio, 1.99; 95% confidence interval, 1.05-3.79). CONCLUSIONS: Switching from a virologically successful first-line boosted PI-containing cART regimen to a non-nucleoside reverse transcriptase inhibitor-containing cART regimen containing either efavirenz or nevirapine is virologically safe, while switching to abacavir-containing cART should be avoided.</description>
<contributor>FHDH-ANRS CO4</contributor>
<date>2011-08</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
